Answer
Ziihera (zanidatamab) is not recommended during pregnancy because its mechanism of action suggests potential foetal harm; no human or animal pregnancy data exist, and other HER2-directed antibodies have been associated with oligohydramnios manifesting as pulmonary hypoplasia, skeletal abnormalities and neonatal death.
Sources for this answer
- Ziihera 300 mg powder for concentrate for solution for infusionJazz Pharmaceuticals Research UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 1Document updated
Sources checked